International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva.
Launched by HOSPITAL UNIVERSITARIO LA PAZ · Jun 9, 2025
Trial Information
Current as of August 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • First local recurrent squamous cell carcinoma of the vulva (SCC).
- • Unifocal, smaller or equal than 4 cm vulvar tumor not involving urethra, vagina or anus.
- • No distant or groin metastasis.
- • To be able to understand the study and sign informed consent.
- • Over 18 years old.
- • To be able to undergo planned follow up.
- Exclusion Criteria:
- • Multifocal recurrent disease of the vulva.
- • Previous bilateral IFL.
- • Synchronous, non-curable second malignancy.
About Hospital Universitario La Paz
Hospital Universitario La Paz, a leading academic medical center in Spain, is dedicated to advancing healthcare through innovative clinical research and trials. With a strong emphasis on patient safety and ethical standards, the hospital collaborates with multidisciplinary teams of healthcare professionals and researchers to conduct cutting-edge studies across various medical fields. Its commitment to excellence in clinical practice, education, and research positions Hospital Universitario La Paz at the forefront of medical advancements, aiming to improve patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported